AGILON HEALTH STOCKHOLDER ALERT: Bragar Eagel & Squire, P.C. Reminds Agilon Health, Inc. Investors of the Upcoming March 2nd Class Action Lead Plaintiff DeadlineBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Agilon (AGL) To Contact Him Directly To Discuss Their Options
Bragar Eagel & Squire, P.C. Urges Beyond Meat, Inc. (NASDAQ: BYND) Investors With Large Losses to Contact the Firm Before March 24thBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Beyond Meat (BYND) To Contact Him Directly To Discuss Their Options
Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discoveryEast Hanover, February 6, 2026 – Novartis today broke ground on a new, state-of-the-art global Biomedical Research center in San Diego, California, designed to provide world-class scientific infrastructure and drug-discovery capabilities to advance the company’s pipeline for patients. Once operational in 2029, the approximately 466,000-square-foot facility is expected to house about 1,000 Novartis employees and integrate seamlessly with Novartis global research sites including Cambridge, Massachusetts, and Basel, Switzerland, enabling integrated discovery efforts across regions. “This new research center will strengthen our scientific leadership and accelerate the discovery of transformative medicines for patients worldwide, while deepening our connectivity with biotech, academic and technology partners across the region,” said Fiona Marshall, President of Biomedical Research at Novartis. “Designed to power future drug discovery, with a focus on genetics and human biology in key therapeutic areas such as neuroscience and oncology, it will create a single Novartis research center within one of the world’s premier life sciences ecosystems—accelerating our pipeline from discovery to patients.” Government leaders and community partners joined Novartis employees in San Diego to mark the start of construction at the groundbreaking ceremony. “This investment by Novartis reinforces San Diego as a place where breakthrough science happens and where innovation translates into high-quality jobs and life-changing medicines,” said Todd Gloria, San Diego Mayor. “San Diego is a global leader in life sciences because we bring together world-class talent, cutting-edge research and a collaborative ecosystem that turns discovery into impact. We’re proud to welcome this new research center and to continue building an economy rooted in innovation and results.” The new facility builds on more than 25 years of Novartis research and development in San Diego and will support end-to-end drug discovery across core disease areas, including neuroscience, global health, oncology and age-related diseases and regenerative medicine. It will also expand the company’s capabilities in next-generation technology platforms, such as gene and cell therapies, RNA-based therapies, biologics and targeted protein degradation, and will advance novel delivery systems that open new therapeutic possibilities. “Rooted in a strong legacy of innovation in San Diego and California, we are inspired to shape the future—driving new breakthroughs that will transform care for millions of patients worldwide,” said Thierry Diagana, California Sites Head and Global Head of Global Health, Biomedical Research, Novartis. With advanced artificial intelligence, data and computational capabilities embedded throughout, the facility will be a key part of the global Novartis Biomedical Research network, helping share insights, scale innovation, and deliver meaningful breakthroughs for patients worldwide. The San Diego research facility is a key pillar of the company’s USD 23 billion US investment. This includes a new flagship manufacturing hub in North Carolina; the opening of a radioligand therapy (RLT) manufacturing facility in Carlsbad, California; investments to expand existing facilities in Indiana and New Jersey; and plans to build new RLT manufacturing facilities in Florida and Texas. Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release; or regarding potential future revenues from such products; or regarding discussions of strategy, plans, expectations or intentions, including discussions regarding our continued investment into new US R&D or manufacturing capabilities. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. Neither can there be any guarantee that the expected benefits from the plans and investments described in this press release will be achieved in the expected timeframe, or at all. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide. Reimagine medicine with us: Visit us at https://www.novartis.us and connect with us on LinkedIn US, X/Twitter US and Instagram US. # # #
Davis Commodities Shareholders Approve Share Consolidation to Boost Share Price and Market StandingSINGAPORE, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Davis Commodities Limited (“Davis Commodities” or the “Company”) announced that shareholders have approved a share consolidation proposal at an Extraordinary General Meeting (EGM) held on February 4, 2026, at Genting Hotel Jurong in Singapore. The measure is aimed at increasing the Company’s share price, regaining compliance with minimum bid price requirements, enhancing market credibility and investor confidence, and moderating excessive share price volatility.
REMINDER -- Aeroméxico Announces Webcast of Fourth Quarter & Full Year 2025 Financial ResultsMEXICO CITY, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Grupo Aeroméxico S.A.B. de C.V. (NYSE: AERO & BMV: AERO) (“Aeroméxico”) will hold a live conference call and webcast on Tuesday, February 17, 2026, at 07:00 a.m. Mexico City Time (08:00 a.m. Eastern Time) to discuss its fourth quarter and full year 2025 financial results.
Evolution Metals & Technologies Corp. to Host Investor & Analyst Webinar on February 19, 2026 at 10 AM ETMIAMI, FL , Feb. 06, 2026 (GLOBE NEWSWIRE) -- Evolution Metals & Technologies Corp. (
NASDAQ: EMAT) (“EM&T”) a company focused on producing a secure, reliable, and vertically integrated global supply chain for critical minerals and materials, today announced it will host an Investor & Analyst Webinar on Thursday, February 19, 2026 at 10 a.m. ET.
Cross-Border Families Warned of Potentially Adverse U.S. Compliance Implications and Taxation of Family TrustsToronto, ON, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Cross-border estate plans created decades ago can trigger severe legal and financial consequences, especially when a Canadian family trust beneficiary becomes a U.S. citizen or resident.
Correction: Astanza Laser Appointed Sole Distributor for Dermalosophy USA Professional SkincareDallas, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Astanza Laser, an award-winning and trusted provider of aesthetic laser technology, service, marketing support, and training, has been appointed the exclusive U.S. distributor for Dermalosophy, a professional dermocosmetics brand praised by skincare experts, aesthetic physicians, and wellness clinics worldwide. Founded, formulated, and manufactured in Israel, Dermalosophy is a professional skincare line rooted in skin health science, delivering clinically driven formulations engineered to support comprehensive, results-oriented treatment plans.
ORACLE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Oracle Corporation and Encourages Investors to Contact the FirmBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Oracle (ORCL) To Contact Him Directly To Discuss Their Options
BYND SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of Beyond Meat, Inc. Investors - Contact Kirby McInerney LLP by March 24, 2026NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased Beyond Meat, Inc. (“Beyond Meat” or the “Company”) (
NASDAQ: BYND) securities to contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost.
HUT 8 ALERT: Bragar Eagel & Squire, P.C. is Investigating Hut 8 Corp. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Hut 8 (HUT) To Contact Him Directly To Discuss Their Options
Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private PlacementTHE WOODLANDS, Texas, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the closing of its previously announced underwritten public offering of 32,000,000 shares of its common stock, par value $0.001, and concurrent private placement of 22,400,000 shares of common stock and 367,145 shares of series b convertible preferred stock (the “Series B Convertible Preferred Stock”). The shares of common stock offered pursuant to the public offering were sold at a public offering price of $1.30 per share and the shares of preferred stock were sold at a price of $65 per share. The offerings closed on February 2, 2026.
Canoe EIT Income Fund Announces February 2026 Monthly Distribution, Quarterly Preferred Distributions and Amendment to Special DistributionCALGARY, Alberta, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Canoe EIT Income Fund (the “Fund”) (TSX - EIT.UN) announces the February 2026 monthly distribution of $0.10 per unit. Additionally, the Fund announces a quarterly distribution for preferred units. Cumulative Redeemable Series 1 (EIT.PR.A) and Series 2 Preferred (EIT.PR.B) unitholders will receive a distribution of $0.30 per unit. Unitholders of record on February 23, 2026, will receive distributions payable on March 13, 2026. Holders of the Fund’s Series 3 Preferred Units will receive an initial partial distribution of $0.1473 per unit, payable on March 16, 2026.
Good360 and the NFL Donate Super Bowl Apparel to Communities WorldwideAlexandria, VA, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Ahead of Super Bowl LX this weekend, the National Football League (NFL) and Good360 are collaborating for the 12th year to ensure unused apparel is responsibly donated to communities around the world, transforming potential waste into meaningful impact.
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hub GroupFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Hub Group To Contact Him Directly To Discuss Their Options
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to one new employee. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employee entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on February 2, 2026 (the “Grant Date”), ORIC granted a total of 173,800 non-qualified stock options and 28,700 restricted stock units to three new non-executive employees who began their employment with ORIC in January 2026.
Onex Completes Convex Acquisition and Strategic Investment by AIGKey drivers of strategy to enhance Onex’ enterprise value through Convex ownership and increased profitability at Onex’ asset management platform
Veeco Stockholders Approve Merger with AxcelisPLAINVIEW, N.Y., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Veeco Instruments Inc. (Nasdaq: VECO) (“Veeco”) today announced that its stockholders have voted to approve all proposals related to the Company’s pending merger (the “Merger”) with Axcelis Technologies, Inc. (Nasdaq: ACLS) (“Axcelis”) at its Special Meeting of Stockholders (“Special Meeting”).
Farmer Brothers Coffee to report fiscal second quarter 2026 financial resultsFORT WORTH, Texas, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Farmer Brothers Coffee Co. (
NASDAQ: FARM), a leading roaster, wholesaler and distributor of coffee, tea and allied products, announced today it will publish its second quarter 2026 financial results for the period ended Dec. 31, 2025 with the filing of its 10-Q and the issuing of its earnings results release, both of which will be posted on the Investor Relations section of its website after the close of market on Friday, Feb. 13.
Crescent Capital BDC, Inc. Reschedules Earnings Release and Conference Call for Fourth Quarter and Fiscal Year Ended December 31, 2025LOS ANGELES, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Crescent Capital BDC, Inc. (the “Company”) (
NASDAQ: CCAP) today announced that it has rescheduled the release of its financial results and accompanying earnings webcast/conference call for the fourth quarter and fiscal year ended December 31, 2025. The Company will now release its financial results for the fourth quarter and fiscal year ended December 31, 2025 on Wednesday, February 25, 2026 after market close and host a webcast/conference call on Thursday, February 26, 2026 at 12:00 p.m. Eastern Time.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on February 2, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 11,500 shares of Class A common stock and restricted stock units (RSUs) underlying 5,750 shares of Class A common stock to two (2) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NAARDEN, The Netherlands and MIAMI, Feb. 06, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 217,000 of NewAmsterdam’s ordinary shares to four (4) non-executive new hires. The share options were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).
METC Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Ramaco Resources, Inc. Class ActionSAN DIEGO, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Ramaco Resources, Inc. (
NASDAQ: METC) securities between July 31, 2025 and October 23, 2025. Ramaco engages in the mining, development, and sale of coal and rare earth minerals.
DraftKings Expands Prediction Markets Catalog in Deal With Crypto.comNew exchange connection brings first player-specific sports event contracts to DraftKings Predictions
CHARMING MEDICAL CLASS ACTION DEADLINE: Bragar Eagel & Squire, P.C. Urges Charming Medical (MCTA) Investors With Large Losses to Contact the Firm Before February 17thBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Charming (MCTA) To Contact Him Directly To Discuss Their Options
Barefoot Paradise: The Bahamas Lands #4 Spot on U.S. News & World Report’s Best Beaches in the WorldNassau, The Bahamas, Feb. 06, 2026 (GLOBE NEWSWIRE) -- The Bahamas has once again earned global recognition as one of the world’s top beach destinations, securing the #4 spot for Best Beaches in the World in U.S. News & World Report’s rankings for 2026.
F5, INC. ALERT: Bragar Eagel & Squire, P.C. Urges F5, Inc. (NASDAQ:FFIV) Investors to Contact the Firm Before February 17th Regarding Their RightsBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In F5 (FFIV) To Contact Him Directly To Discuss Their Options
Bragar Eagel & Squire, P.C. Reminds Klarna Group plc Investors of the Upcoming February 20th Lead Plaintiff Deadline for the Filed Class Action LawsuitBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Klarna (KLAR) To Contact Him Directly To Discuss Their Options
Critical Minerals Leader Element3 Launches Lithium Carbonate Production in Permian Basin, Marking America’s First New Lithium Mining in More than Half a CenturyThe Honorable Governor Greg Abbott, United States Department of Energy Chief Commercial Officer Anthony Pugliese and Texas Railroad Commissioner Wayne Christian Join Element3 CEO Hood Whitson to Celebrate Watershed Moment in Country’s History
RR Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Richtech Robotics Inc. Class ActionSAN DIEGO, Calif., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Richtech Robotics Inc. (
NASDAQ: RR) securities between January 27, 2026 and 12:00 PM EST on January 29, 2026. Richtech describes itself as a “robotics and artificial intelligence (“AI”) technology company focused on developing advanced embodied AI systems that aims to improve the efficiency and productivity of U.S. businesses.”
Base Carbon Announces Shareholder Meeting ResultsTORONTO, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Base Carbon Inc. (Cboe CA: BCBN) (OTCQX: BCBNF) with operations through its wholly-owned subsidiary, Base Carbon Capital Partners Corp. (together, with affiliates, “Base Carbon”, or the “Company”), is pleased to announce the results of its Special Shareholder Meeting (the “Meeting”).
SBA Suspends 111,620 California Borrowers Suspected of Committing $8.6 Billion in Pandemic-Era FraudWASHINGTON, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Today, following a visit to San Diego, U.S. Small Business Administration (SBA) Administrator Kelly Loeffler announced that the agency has suspended 111,620 California borrowers amid suspected fraudulent activity across SBA pandemic-era loan programs. In total, these borrowers received 118,489 Paycheck Protection Program (PPP) and Economic Injury Disaster Loans (EIDL) loans totaling over $8.6 billion.
IPG Launches Palisade® Butyl-HT PLUS: The Premium 100% Pure Butyl Underlayment for Extreme Weather PerformanceSARASOTA, Fla., Feb. 06, 2026 (GLOBE NEWSWIRE) -- IPG (Intertape Polymer Group) today announced the launch of Palisade Butyl-HT PLUS, a high-performance, non-asphaltic, 100% pure butyl underlayment. Engineered for steep-slope roofing, this premium solution is designed to withstand extreme thermal conditions while providing superior safety for the installer.
Transaction in Own SharesTransaction in Own Shares
Ahead of the Big Game, Signature Aviation Opens Human Trafficking Awareness Training to General Aviation IndustryThe initiative reflects the company’s broader commitment to collective action with trusted partners, community impact
Old National Names Joe Chasteen Chief Revenue Enablement OfficerEVANSVILLE, Ind., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Old National Bancorp (“Old National”) has appointed Joe Chasteen to the role of Chief Revenue Enablement Officer, a newly-created strategic leadership position focused on organic growth and revenue generation.
Sitewire Named to HousingWire's 2026 Tech100 Real Estate AwardsConstruction draw management platform recognized for transforming how lenders fund and manage construction loans
ORCL Investors Have Opportunity to Lead Oracle Corporation Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, Feb. 06, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Oracle Corporation (“Oracle” or “the Company”) (
NYSE: ORCL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
AtlasFX’s BankMinder Wins Treasury Fintech Solution of the Year at Trade Treasury Payments AwardsSAN FRANCISCO, Feb. 06, 2026 (GLOBE NEWSWIRE) -- AtlasFX, a leading SaaS platform for foreign exchange (FX) risk management, today announced that its BankMinder module has been named Treasury Fintech Solution of the Year at the 2026 Trade Treasury Payments Awards. The awards recognize excellence and innovation across trade, treasury, payments and risk technology.
YES Communities Releases 2025 Philanthropic Initiative RecapDenver, CO, Feb. 06, 2026 (GLOBE NEWSWIRE) -- YES Communities today announced the release of its 2025 Philanthropic Initiative Recap, outlining the impact of its YES We Care programs, which contributed nearly $380,000 in support for residents, team members and communities throughout the year.
Cobalt Watches Introduces Bold Timepieces Crafted for Everyday WearAvailable in Seven Distinct Styles, Featuring Durable Construction, Striking Design and Accessible Pricing
R1 Appoints Andy Brailo as Chief Commercial OfficerCHICAGO, Feb. 06, 2026 (GLOBE NEWSWIRE) -- R1 (“R1” or the “Company”), the leader in healthcare revenue management, today announced that Andy Brailo has joined the Company as Chief Commercial Officer. In this role, Mr. Brailo will oversee R1’s growth and revenue strategy and is expected to scale commercial capabilities, expand its customer base and enhance go-to-market execution to meet increasing demand for R1’s AI-enabled solutions.
RegEd’s Xchange Alerts Solution Surpasses 300 Million Data Updates, Reinforcing Industry Leadership in Automated Producer Data ReconciliationThe industry’s most trusted solution for rules-based producer data reconciliation continues to scale, helping insurers and distributors reduce NIGOs and maintain accurate, real-time producer data through sustained innovation and adoption.
Tai Software and OpenTrack Announce Integration Bringing AI-Native End-to-End Container Visibility Directly into Tai TMSHUNTINGTON BEACH, Calif., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Tai Software, a leading transportation management system (TMS) for freight brokers, today announced a new integration with OpenTrack that will deliver AI-ready, end-to-end container visibility data directly inside Tai’s platform.
DP World, President Abinader Advance Dominican Republic Hub VisionDialogue focused on strengthening the Dominican Republic’s role in global supply chains as a logistics and nearshoring hub
Futurum Equities Appoints Industry Veteran Rolf Bulk as Head of Semiconductor & Infrastructure Equity Research•Futurum Equities leverages proprietary benchmarking, surveys, and teardown-driven insights, alongside Futurum Group’s industry network, to deliver institutional-grade analysis and stock coverage; Expanded sell-side coverage across global semiconductors and AI infrastructure will be added to Futurum’s AI ‘Living Intelligence’ platform powering users’ direct interaction
Yachting: 18th Economic Symposium in Monaco, Sustainability Redefines the Future of Nautical IndustryMONACO, Feb. 06, 2026 (GLOBE NEWSWIRE) -- In the international debate on the future, yachting today occupies a singular position: a sector that embodies excellence while also serving as an advanced laboratory for the major environmental and economic transitions of our time. The 18th Economic Symposium - La Belle Classe Superyachts of the Yacht Club de Monaco - an annual event bringing together owners, shipyards, designers, financial operators, institutions and international media -clearly captured this historic turning point, framing 2035 not as a distant horizon but as a variable already embedded in today’s industrial, financial and design decisions.
GAUZY FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Gauzy Ltd Investors with Large Losses to Contact the Firm Before February 6th Lead Plaintiff DeadlineBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Gauzy (GAUZ) To Contact Him Directly To Discuss Their Options
NTE Welcomes Players Back With New Content for ‘Co-Ex Test’ in 2026Registration Open Now on PC and PlayStation 5 Ahead of Upcoming Closed Beta
Remitly to Report Fourth Quarter and Full Year 2025 Financial Results on February 18, 2026SEATTLE , Feb. 06, 2026 (GLOBE NEWSWIRE) -- Remitly Global, Inc. (
NASDAQ: RELY) (“Remitly”), a trusted provider of financial services that transcend borders, today announced that it will report fourth quarter and full year 2025 financial results after the market closes on Wednesday, February 18, 2026. Management will host a conference call and live webcast to present the Company's financial results and answer questions from the financial analyst community at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time that same evening. Conference call and webcast information can be found below.
Joveo’s 2026 Recruiting Benchmarks Report Reveals Up to 9x Growth in Applicant Volume Over the Past Three YearsThe report uncovers a tale of two labor markets; shares what the difference means for recruiting and how talent acquisition teams should adapt their strategy in 2026
PMI Investors Have Opportunity to Lead Picard Medical, Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, Feb. 06, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Picard Medical, Inc. (“Picard” or “the Company”) (NYSE American: PMI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
RR Investors Have Opportunity to Lead Richtech Robotics Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, Feb. 06, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Richtech Robotics Inc. (“Richtech” or “the Company”) (
NASDAQ: RR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
PLI Announces Collaboration with CPE Studios to Offer First-Ever Documentary-Style CPE and CLE ProgramsNEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Practising Law Institute (PLI), a nonprofit learning organization dedicated to keeping professionals at the forefront of legal and regulatory developments, has released a new video series in collaboration with CPE Studios, an educational content creator known for its immersive learning experiences.
METC Investors Have Opportunity to Lead Ramaco Resources, Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, Feb. 06, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ramaco Resources, Inc. (“Ramaco” or “the Company”) (
NASDAQ: METC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
BRBR Investors Have Opportunity to Lead BellRing Brands, Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, Feb. 06, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BellRing Brands, Inc. (“BellRing” or “the Company”) (
NYSE: BRBR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
BYND Investors Have Opportunity to Lead Beyond Meat, Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, Feb. 06, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Beyond Meat, Inc. (“Beyond Meat” or “the Company”) (
NASDAQ: BYND) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, Feb. 06, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc. (“Vistagen” or “the Company”) (
NASDAQ: VTGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
BBWI Investors Have Opportunity to Lead Bath & Body Works, Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, Feb. 06, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bath & Body Works, Inc. (“Bath & Body Works” or “the Company”) (
NYSE: BBWI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
